PBYI vs REGN · P/E 4.3, rev $56.5M vs P/E 14, rev $4.29B
Puma Biotechnology Inc (PBYI) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PBYI currently screens at market cap $165.3M and trailing P/E 4.3. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PBYI and REGN stock pages for the full models.
Not investment advice.